Novel insights into mesothelioma biology and implications for therapy

Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.

[1]  R. Doll.  Mortality from Lung Cancer in Asbestos Workers , 1955 .

[2]  J. Wagner,et al.  Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.

[3]  J. Millis.  Challenges ahead , 1998, Nature.

[4]  E. C. Hammond,et al.  ASBESTOS EXPOSURE AND NEOPLASIA. , 1964, JAMA.

[5]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[6]  Y. Bariş,et al.  Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study. , 1979, Journal of the National Cancer Institute.

[7]  F. Huth,et al.  Carcinogenicity studies on fibres, metal compounds, and some other dusts in rats. , 1987, Experimental pathology.

[8]  M. Newhouse,et al.  Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area , 1993, British journal of industrial medicine.

[9]  F Rey,et al.  Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis , 1993, Cancer.

[10]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[11]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[12]  J. Fletcher,et al.  Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.

[13]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[14]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[15]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[17]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[18]  B. Mossman,et al.  Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. , 1996, Cancer research.

[19]  D. Fitzpatrick,et al.  Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. , 1996, Cancer research.

[20]  E. Kagan,et al.  Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. , 1998, American journal of respiratory cell and molecular biology.

[21]  R. Kratzke,et al.  Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression , 1998, Oncogene.

[22]  D. Carson,et al.  Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC) , 1998, Oncogene.

[23]  H. Strander,et al.  Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. , 1998, Anticancer research.

[24]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[25]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[26]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[27]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[28]  J. Cheng,et al.  Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two‐hit mechanism of NF2 inactivation , 1999, Genes, chromosomes & cancer.

[29]  A. Casalini,et al.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma , 2001, The Journal of pathology.

[30]  R. Kratzke,et al.  Inactivation of p16INK4a expression in malignant mesothelioma by methylation. , 2002, Lung cancer.

[31]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Pietro Comba,et al.  Pleural Mesothelioma Cases in Biancavilla are Related to a New Fluoro-Edenite Fibrous Amphibole , 2003, Archives of environmental health.

[33]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Anne Janin,et al.  Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours , 2003, Oncogene.

[35]  S. Mutsaers.  Mesothelial Cell , 2020, Definitions.

[36]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[37]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[38]  E. van Marck.  Pathology of malignant mesothelioma. , 2004, Lung cancer.

[39]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[40]  J. Shamash,et al.  Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Jhanwar,et al.  A mouse model recapitulating molecular features of human mesothelioma. , 2005, Cancer research.

[42]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[44]  S. Jhanwar,et al.  Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK , 2006, Oncogene.

[45]  D. Fennell,et al.  In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.

[46]  T. Joshi,et al.  Asbestos Ban in India , 2006, Annals of the New York Academy of Sciences.

[47]  Salih Emri,et al.  Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. , 2006, Cancer research.

[48]  Claudio Bianchi,et al.  Malignant mesothelioma: global incidence and relationship with asbestos. , 2007, Industrial health.

[49]  I. Pastan,et al.  Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. , 2007, Cancer immunity.

[50]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[51]  R. Kratzke,et al.  Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. , 2008, Anticancer research.

[52]  B. Christensen,et al.  Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma , 2008, Carcinogenesis.

[53]  Y. Yatabe,et al.  YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. , 2008, Carcinogenesis.

[54]  H. Burris,et al.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer , 2009, Investigational New Drugs.

[55]  F. Galateau-Sallé,et al.  Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas , 2008, Virchows Archiv.

[56]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[57]  A. Darabi,et al.  Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy , 2009, Cancer Immunology, Immunotherapy.

[58]  M. J. van de Vijver,et al.  A conditional mouse model for malignant mesothelioma. , 2008, Cancer cell.

[59]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[60]  B. Christensen,et al.  Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. , 2009, Cancer research.

[61]  Mitchell Ho,et al.  A Binding Domain on Mesothelin for CA125/MUC16* , 2009, Journal of Biological Chemistry.

[62]  J. Soria,et al.  From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Lucito,et al.  Genomic events associated with progression of pleural malignant mesothelioma , 2009, International journal of cancer.

[64]  R. M. Simpson,et al.  Integrated Systems and Technologies Cancer Research Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma , 2010 .

[65]  Jonathan A. Cooper,et al.  Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus , 2010, Cell.

[66]  H. Hoogsteden,et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.

[67]  H. Hoogsteden,et al.  Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. , 2010, American journal of respiratory and critical care medicine.

[68]  H. Pass,et al.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.

[69]  B. Delage,et al.  Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer , 2010, International journal of cancer.

[70]  M. Nimwegen,et al.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma , 2010, British Journal of Cancer.

[71]  H. Hoogsteden,et al.  Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity , 2010, Journal of biomedicine & biotechnology.

[72]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[73]  D. Henderson,et al.  Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  M. Sadelain,et al.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma , 2011, Cancer Immunology, Immunotherapy.

[75]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[76]  David A. Smith,et al.  An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. , 2011, Clinical colorectal cancer.

[77]  F. Liu,et al.  Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy , 2011, Clinical Cancer Research.

[78]  J. Peto,et al.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study , 2011, The Lancet. Oncology.

[79]  Y. Kondo,et al.  LATS2 is a tumor suppressor gene of malignant mesothelioma. , 2011, Cancer research.

[80]  M. Carbone,et al.  Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma , 2011, Clinical Cancer Research.

[81]  Sharyn I. Katz,et al.  A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. , 2011, American journal of respiratory and critical care medicine.

[82]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[83]  M. Jaurand,et al.  Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases , 2011, Journal of toxicology and environmental health. Part B, Critical reviews.

[84]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[85]  Y. Kondo,et al.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes , 2012, Oncogene.

[86]  A. Gazdar,et al.  Malignant mesothelioma: Facts, Myths, and Hypotheses , 2012, Journal of cellular physiology.

[87]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[88]  Xiaobo Cao,et al.  Molecular pathogenesis of malignant mesothelioma , 2012, Expert Reviews in Molecular Medicine.

[89]  M. Maio,et al.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.

[90]  S. Steinberg,et al.  Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression , 2013, Science Translational Medicine.

[91]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[92]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[93]  M. Carbone,et al.  Asbestos is not just asbestos: an unrecognised health hazard. , 2013, The Lancet. Oncology.

[94]  Helen Yu,et al.  Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair , 2013, Proceedings of the National Academy of Sciences.

[95]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[96]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  H. Pass,et al.  Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. , 2013, The American journal of pathology.

[98]  C. Verschraegen,et al.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. , 2013, The American journal of pathology.

[99]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[100]  J. Aerts,et al.  Tumor-associated macrophages in thoracic malignancies. , 2013, Lung cancer.

[101]  E. Puré,et al.  Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity , 2013, Cancer Immunology Research.

[102]  J. Gagné,et al.  Germline mutations in BAP1 impair its function in DNA double-strand break repair. , 2014, Cancer research.

[103]  H. Hoogsteden,et al.  Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma , 2014, PloS one.

[104]  J. Fletcher,et al.  Multipoint targeting of the PI3K/mTOR pathway in mesothelioma , 2014, British Journal of Cancer.

[105]  I. Pastan,et al.  Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma , 2014, Clinical Cancer Research.

[106]  Andrea I. McClatchey,et al.  Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship , 2014, Science Translational Medicine.

[107]  S. Steinberg,et al.  Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 , 2014, Cancer.

[108]  S. Pastorino,et al.  Evaluation of clonal origin of malignant mesothelioma , 2014, Journal of Translational Medicine.

[109]  Mark Cobbold,et al.  Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study , 2014, PLoS biology.

[110]  H. Hoogsteden,et al.  Immunotherapy prospects in the treatment of lung cancer and mesothelioma. , 2014, Translational lung cancer research.

[111]  Anke Mayer-Bartschmid,et al.  Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect , 2014, Molecular Cancer Therapeutics.

[112]  I. Pastan,et al.  Discovery of mesothelin and exploiting it as a target for immunotherapy. , 2014, Cancer research.

[113]  C. Bianchi,et al.  Global mesothelioma epidemic: Trend and features , 2014, Indian journal of occupational and environmental medicine.

[114]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[115]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[116]  M. Meyerson,et al.  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. , 2015, Cancer research.

[117]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[118]  Adam Byron,et al.  Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity , 2015, Cell.

[119]  David R. Jones,et al.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers , 2015, Oncoimmunology.

[120]  W. Thomas,et al.  Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients , 2015, British Journal of Cancer.

[121]  E. Puré,et al.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.

[122]  G. Scagliotti,et al.  Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[123]  D. Collins,et al.  Response evaluation in mesothelioma: Beyond RECIST. , 2015, Lung cancer.

[124]  J. Fletcher,et al.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans , 2015, Molecular Cancer Therapeutics.

[125]  J. V. van Meerbeeck,et al.  This item is the archived peer-reviewed author-version of: Targeting immune checkpoints : new opportunity for mesothelioma treatment? , 2022 .

[126]  K W Schmid,et al.  MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53 , 2015, British Journal of Cancer.

[127]  Shiliang Huang,et al.  CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. , 2015, International journal of clinical and experimental medicine.

[128]  H. Osada,et al.  Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells , 2015, Cancer science.

[129]  A. Gemma,et al.  Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[130]  S. Armstrong,et al.  Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.

[131]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[132]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[133]  Raghav Sundar,et al.  Combining Molecularly Targeted Agents: Is More Always Better? , 2016, Clinical Cancer Research.

[134]  M. Zauderer,et al.  Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[135]  S. Pastorino,et al.  Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma , 2016, Oncogene.

[136]  A. Russo,et al.  The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? , 2016, Critical reviews in oncology/hematology.

[137]  K. Nackaerts,et al.  Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. , 2016 .

[138]  P. Conte,et al.  Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. , 2016, Critical reviews in oncology/hematology.

[139]  John Quackenbush,et al.  Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. , 2016, Cancer research.

[140]  T. Golub,et al.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.

[141]  N. Le Stang,et al.  Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.

[142]  J. Nemunaitis,et al.  Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). , 2016 .

[143]  J. Nemunaitis,et al.  A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). , 2016 .

[144]  P. Jänne,et al.  Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors , 2016, Cancer Immunology Research.

[145]  A. Krasinskas,et al.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma , 2016, Modern Pathology.

[146]  Michel Sadelain,et al.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. , 2016, Cancer discovery.

[147]  J. Aerts,et al.  Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[148]  R. Stahel,et al.  Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma , 2016, Molecular Cancer Therapeutics.

[149]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[150]  Juanita Lopez,et al.  Immuno-oncology combinations: raising the tail of the survival curve , 2016, Cancer biology & medicine.

[151]  J. Testa,et al.  Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations. , 2016, Cancer research.

[152]  H. Hoogsteden,et al.  Extended Tumor Control after Dendritic Cell Vaccination with Low Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma at a Glance Commentary , 2022 .

[153]  S. Novello,et al.  A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM). , 2016 .

[154]  J. Vansteenkiste,et al.  Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[155]  S. Pastorino,et al.  High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma , 2016, Proceedings of the National Academy of Sciences.

[156]  Sharyn I. Katz,et al.  Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy , 2016, Clinical Cancer Research.

[157]  Manish R. Patel,et al.  Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. , 2016 .

[158]  T. Sio,et al.  Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma. , 2016, Anticancer research.

[159]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[160]  A. Farioli,et al.  Radiation‐induced mesothelioma among long‐term solid cancer survivors: a longitudinal analysis of SEER database , 2016, Cancer medicine.

[161]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[162]  H. Hoogsteden,et al.  Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  H. Hoogsteden,et al.  OA13.06 Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys®) in Patients with Mesothelioma: Final Results of a Phase I Study , 2017 .

[164]  S. Beck,et al.  Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial , 2017, JAMA oncology.

[165]  U. Banerji,et al.  Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. , 2017, European journal of cancer.

[166]  J. Aerts,et al.  Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. , 2017, Lung cancer.

[167]  P. Baas,et al.  OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies , 2017 .

[168]  G. Cook,et al.  Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  F. Sotgia,et al.  Anti-CTLA-4 therapy for malignant mesothelioma. , 2017, Immunotherapy.

[170]  J. Aerts,et al.  Checkpoint Blockade in Lung Cancer and Mesothelioma , 2017, American journal of respiratory and critical care medicine.

[171]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[172]  P. Schil.  Faculty Opinions recommendation of Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2018 .